Please ensure Javascript is enabled for purposes of website accessibility

Agenus Stock Rises Ahead of Investor Day Presentation

By Maxx Chatsko - Feb 19, 2020 at 2:49PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The biopharma is scheduled to update investors and Wall Street analysts on two important pipeline programs on Feb. 20.

What happened

Shares of Agenus (AGEN 11.24%) rose as much as 12.1% today. While there wasn't any specific news lifting the stock, investors are anticipating good news ahead of the company's investor day, scheduled for tomorrow. 

The development-stage biopharmaceutical company is set to present clinical data from two drug candidates at the investor day: a combination therapy comprising AGEN2034 and AGEN1884, and AGEN1181 as a monotherapy. All three experimental therapies are monoclonal antibodies being developed as oncology assets.

As of 3:04 p.m. EST, the pharma stock was trading at its intraday high representing a 12.1% gain.

An arrow bouncing up shelves on a wall.

Image source: Getty Images.

So what

In late December, Agenus initiated a phase 1/2 clinical trial of its therapy combining the company's two lead drug candidates: AGEN2034 (balstilimab) and AGEN1884 (zalifrelimab). The former inhibits CTLA-4, while the latter inhibits PD-1. Both proteins are common targets of oncology drugs, but there's always room to demonstrate more effective inhibition with fewer side effects, especially in advanced cancers. 

Agenus is also expected to report data from a dose escalation study of AGEN1181. The monoclonal antibody is a next-generation anti-CTLA-4 drug candidate, and has been designed to be more potent against tumors relying on CTLA-4 mutations.

Now what

Investors are clearly intrigued by the company's technology platform, but the excitement must be supported by promising clinical results. Agenus will get the first chance to share meaningful early-stage results for its current pipeline at its investor day. If all goes well, it wouldn't be surprising if the company raises more funding through a public stock offering to take advantage of a soaring stock price. But first things first: Let's see the data.

Maxx Chatsko has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Agenus Inc. Stock Quote
Agenus Inc.
$2.97 (11.24%) $0.30

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/14/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.